Efficacy and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer: a systematic review and network meta-analysis

Many studies have been conducted to evaluate the effectiveness and safety of immune checkpoint inhibitors in metastatic breast cancer, but the results were not conclusive. The present network meta-analysis aimed to assess the effectiveness and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer. PubMed, Scopus, Web of Science, The Cochrane Library and ClinicalTrials.gov were searched. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Safety was considered as secondary outcomes. Cochrane Risk-Of-Bias (RoB2) was used for the quality assessment of relevant articles. Random effect model was used for meta-analysis in the clinically relevant subgroups ( e.g., PD-L1/PD-1±, previously untreated/ refractory, and triple negative/hormone positive). In this network meta-analysis, 9 studies ( n =3785) were included. Our results revealed that in triple negative breast cancer patients, only durvalumab was associated with statistically significant improved OS (HR=0.49, 95%CrI=[0.30,0.80]) and atezolizumab + chemotherapy improved significantly PFS (HR=0.70,95%CrI=[0.38,0.92]). In PD-L1 positive subgroup, only atezolizumab + chemotherapy significantly improved PFS (HR=0.68,95%CrI=[0.42,0.99]) and OS (HR=0.63,95%CrI=[0.35,0.92]) compared with chemotherapy. In previously untreated subjects, only atezolizumab + chemotherapy significantly improved PFS (HR= 0.70, 95% CrI= [0.37, 0.91]) compared with chemotherapy. No significant difference was observed in adverse events of the comparisons while pembrolizumab + chemotherapy had more probability to cause adverse events when compared with chemotherapy. PD-1/PD-L1 inhibitors can more significantly improve PFS in the PD-L1 positive, previously untreated and metastatic triple negative breast cancer patients. However, more high-qualified trials must be still conducted to provide more definitive result for clinical practice.

Authors

Institutions

Publication Details

Journal
European journal of medical research
Published
2026-11-12
DOI
https://doi.org/10.1186/s40001-026-05405-6
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer: a systematic review and network meta-analysis

Erfan Sadeghi, Mehran Beyki, Vajihe Akbari, Reza Amiri Khosroshahi et al.
European journal of medical research
Cancer Immunotherapy and Biomarkers
article

Efficacy and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer: a systematic review and network meta-analysis

Erfan Sadeghi, Mehran Beyki, Vajihe Akbari, Reza Amiri Khosroshahi, Azadeh Moghaddas, Shakiba Fathzadeh
article en

Abstract

Many studies have been conducted to evaluate the effectiveness and safety of immune checkpoint inhibitors in metastatic breast cancer, but the results were not conclusive. The present network meta-analysis aimed to assess the effectiveness and safety of PD-1/PD-L1 inhibitors in different types of metastatic breast cancer. PubMed, Scopus, Web of Science, The Cochrane Library and ClinicalTrials.gov were searched. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Safety was considered as secondary outcomes. Cochrane Risk-Of-Bias (RoB2) was used for the quality assessment of relevant articles. Random effect model was used for meta-analysis in the clinically relevant subgroups ( e.g., PD-L1/PD-1±, previously untreated/ refractory, and triple negative/hormone positive). In this network meta-analysis, 9 studies ( n =3785) were included. Our results revealed that in triple negative breast cancer patients, only durvalumab was associated with statistically significant improved OS (HR=0.49, 95%CrI=[0.30,0.80]) and atezolizumab + chemotherapy improved significantly PFS (HR=0.70,95%CrI=[0.38,0.92]). In PD-L1 positive subgroup, only atezolizumab + chemotherapy significantly improved PFS (HR=0.68,95%CrI=[0.42,0.99]) and OS (HR=0.63,95%CrI=[0.35,0.92]) compared with chemotherapy. In previously untreated subjects, only atezolizumab + chemotherapy significantly improved PFS (HR= 0.70, 95% CrI= [0.37, 0.91]) compared with chemotherapy. No significant difference was observed in adverse events of the comparisons while pembrolizumab + chemotherapy had more probability to cause adverse events when compared with chemotherapy. PD-1/PD-L1 inhibitors can more significantly improve PFS in the PD-L1 positive, previously untreated and metastatic triple negative breast cancer patients. However, more high-qualified trials must be still conducted to provide more definitive result for clinical practice.

European journal of medical research
Isfahan University of Medical Sciences (IR), Shiraz University of Medical Sciences (IR), Shahid Sadoughi University of Medical Sciences and Health Services (IR), Tehran University of Medical Sciences (IR)
Isfahan University of Medical Sciences
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon